158 related articles for article (PubMed ID: 18716976)
1. Trichomegaly induced by erlotinib.
Papadopoulos R; Chasapi V; Bachariou A
Orbit; 2008; 27(4):329-30. PubMed ID: 18716976
[TBL] [Abstract][Full Text] [Related]
2. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva).
Márquez G; Herrera-Acosta E; Vidal I; Galvany L; Iglesias M; Umbert P
Int J Dermatol; 2009 Jan; 48(1):97-8. PubMed ID: 19126063
[No Abstract] [Full Text] [Related]
3. Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
Vergou T; Stratigos AJ; Karapanagiotou EM; Matekovits AE; Dilana KD; Tsimboukis S; Antoniou C; Chasapi V; Syrigos KN
J Am Acad Dermatol; 2010 Aug; 63(2):e56-8. PubMed ID: 20633793
[No Abstract] [Full Text] [Related]
4. Trichomegaly secondary to erlotinib.
Desai RU; Rachakonda LP; Saffra NA
Can J Ophthalmol; 2009 Dec; 44(6):e65. PubMed ID: 20052001
[No Abstract] [Full Text] [Related]
5. Ocular side effects and trichomegaly of eyelashes induced by erlotinib: a case report and review of the literature.
Celik T; Kosker M
Cont Lens Anterior Eye; 2015 Feb; 38(1):59-60. PubMed ID: 25249292
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib-induced trichomegaly in a male patient with pancreatic cancer.
Saif MW; Gnanaraj J
Cutan Ocul Toxicol; 2010 Mar; 29(1):62-6. PubMed ID: 19954400
[TBL] [Abstract][Full Text] [Related]
7. Persistent hair growth during treatment with the EGFR inhibitor erlotinib.
Alexandrescu DT; Kauffman CL; Dasanu CA
Dermatol Online J; 2009 Mar; 15(3):4. PubMed ID: 19379648
[TBL] [Abstract][Full Text] [Related]
8. Acquired trichomegaly: trichomegaly secondary to erlotinib.
Medina Mendez CA; Ma PC; Singh AD
JAMA Ophthalmol; 2014 Sep; 132(9):1051. PubMed ID: 25078467
[No Abstract] [Full Text] [Related]
9. Erlotinib-associated trichomegaly.
Lane K; Goldstein SM
Ophthalmic Plast Reconstr Surg; 2007; 23(1):65-6. PubMed ID: 17237698
[TBL] [Abstract][Full Text] [Related]
10. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
Braiteh F; Kurzrock R; Johnson FM
J Clin Oncol; 2008 Jul; 26(20):3460-2. PubMed ID: 18612164
[No Abstract] [Full Text] [Related]
11. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
Zhang G; Basti S; Jampol LM
Cornea; 2007 Aug; 26(7):858-60. PubMed ID: 17667622
[TBL] [Abstract][Full Text] [Related]
12. Toxicity manifesting as cosmetic hair alterations during erlotinib treatment.
Kudo K; Fujiwara K; Tsushima M; Mizuta M; Matsuo K; Yonei T; Sato T
Acta Oncol; 2011 Jan; 50(1):146-8. PubMed ID: 20843170
[No Abstract] [Full Text] [Related]
13. Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer.
Forde P; Murphy C; O'Sullivan C; Carney D
Ir J Med Sci; 2011 Mar; 180(1):283-4. PubMed ID: 20108129
[TBL] [Abstract][Full Text] [Related]
14. Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
Rodriguez NA; Ascaso FJ
J Clin Oncol; 2011 Jun; 29(18):e532-3. PubMed ID: 21483009
[No Abstract] [Full Text] [Related]
15. Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
Gerber PA; Enderlein E; Homey B; Muller A; Boelke E; Budach W
J Clin Oncol; 2007 Oct; 25(29):4697-8; author reply 4698-9. PubMed ID: 17925571
[No Abstract] [Full Text] [Related]
16. Fulminant hepatic failure secondary to erlotinib.
Liu W; Makrauer FL; Qamar AA; Jänne PA; Odze RD
Clin Gastroenterol Hepatol; 2007 Aug; 5(8):917-20. PubMed ID: 17625975
[TBL] [Abstract][Full Text] [Related]
17. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer.
Carser JE; Summers YJ
J Thorac Oncol; 2006 Nov; 1(9):1040-1. PubMed ID: 17409992
[No Abstract] [Full Text] [Related]
18. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
19. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
20. Trichomegaly of the eyelashes after colorectal cancer treatment with the epidermal growth factor receptor inhibitor cetuximab.
Bambury R; McCaffrey JA
Clin Colorectal Cancer; 2009 Oct; 8(4):235. PubMed ID: 19822516
[No Abstract] [Full Text] [Related]
[Next] [New Search]
